RARRES2 and obesity disorder: Although chemerin is implicated in the pathogenesis of obesity-related metabolic and cardiovascular disorders, no pharmacological agents that specifically target the chemerin/CMKLR1 axis, including PVAT-derived chemerin, are currently available.